Reconnect Labs is a Swiss, clinical stage pharmaceutical company developing Regenerative Therapeutics™ for mental health.
Our team works at the forefront of neuroscience and precision psychopharmacology, originating a portfolio that includes sublingual formulations of DMT & Harmine for affective disorders (RE01), 5 MeO-DMT for chronic pain (RE02), and Dexmedetomidine for insomnia (RE03).
Our team works at the forefront of neuroscience and precision psychopharmacology, originating a portfolio that includes sublingual formulations of DMT & Harmine for affective disorders (RE01), 5 MeO-DMT for chronic pain (RE02), and Dexmedetomidine for insomnia (RE03).
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Switzerland
Year Founded:
2021
Main Therapeutic Focus:
CNS/Neurological
Lead Product in Development:
sublingual formulation of DMT & Harmine for affective disorders (RE01)
Development Phase of Primary Product:
Phase II
Number Of Unlicensed Products (For Which You Are Seeking Partners):
3
Speaker
.jpg)
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
